Mutational Resistance Expected with Mass Indiscriminate Nirsevimab Injection of Infants <~ Courageous Discourse | Dr Peter McCullough

Analysis Demonstrates RSV Will Easily Mutate to Escape Monoclonal Antibodies

PETER MCCULLOUGH, MD JAN 11, 2024     READ | LISTEN

The US FDA repeatedly pulled monoclonal antibodies against SARS-CoV-2 off the market because modeling studies demonstrated emerging mutational resistance. I wondered if the same challenges will exist for nirsevimab (Beyfortis, Sanofi, AstraZeneca) which have been injected in newborns on a mass indiscriminate basis since October, 2023 for the theoretical prevention of respiratory syncytial virus (RSV).

Unknown's avatar

About michael burgwin

A child of the peace and antiWar movements, a Truther with self-diagnosed Opposition Defiance Disorder, formerly politically liberal tho now politically marooned, and Post-Doomer, on any issue, I trend to the conspiracy side, sort through the absurd, fantastical and insane, until I find firm ground usually located just the other side of the censorship firewall of propaganda and orthodoxy, dogma, and other either / or thinking.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a comment